Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03430297
Brief Title: A Phase Ⅲ Study to Investigate JS001 Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma

First Submitted : January 29, 2018
First Submitted that Met QC Criteria : February 5, 2018
First Posted : February 12, 2018

Last Update Submitted that Met QC Criteria : May 9, 2018
Last Update Posted : May 10, 2018 (Estimate)